Table 5. Clinical characteristics of the control group patients who were CAP-identified HS with or without US-identified HS.
| Variables | CAP ≥ 238 dB/m combined with US-identified HS (N = 160) | CAP ≥ 238 dB/m without US-identified HS (N = 32) | P value |
|---|---|---|---|
| Age(yr) | 57.7±11.8 | 58.4±10.3 | 0.767 |
| Male | 81 (50.6%) | 17 (53.1%) | 0.796 |
| BMI (kg/m2) | 0.825 | ||
| <24 | 33 (21.3%) | 7 (23.3%) | |
| 24–30 | 91 (58.7%) | 16 (53.3%) | |
| >30 | 31 (20.0%) | 7 (23.3%) | |
| DM (%) | 73 (45.6%) | 10 (31.25%) | 0.134 |
| AST (IU/L) | 36.5±25.0 | 42.2±22.1 | 0.364 |
| ALT (IU/L) | 46.2±32.1 | 35.7±19.8 | 0.139 |
| Bilirubin (mg/dL) | 0.9±0.7 | 1.7±2.3 | 0.015 |
| Albumin (g/dL) | 4.7±0.3 | 4.3±0.4 | <0.001 |
| Fasting sugar (mg/dL) | 116.4±31.5 | 107.9±32.0 | 0.353 |
| HDL, male< 40, female < 50(mg/dL) | 28 (20%) | 6 (20.7%) | 0.933 |
| LDL (mg/dL) | 99.5±30.7 | 101.5±41.5 | 0.770 |
| Total cholesterol (mg/dL) | 182.6±34.9 | 183.3±44.3 | 0.919 |
| VLDL(mg/dL) | 26.8±12.5 | 24.4±14.6 | 0.374 |
| Triglyceride >150 (mg/dL) | 45 (32.4%) | 7 (24.1%) | 0.383 |
| Platelet<150 (1000/μL) | 6 (9.8%) | 7 (50.0%) | <0.001 |
| LSM (kPa) | 5.3 (4.4–7.85) | 10 (5.3–25) | <0.001 |
| CAP (dB/m) | 293.5 (269–330.5) | 269.5 (251–302) | 0.004 |
BMI, body mass index; DM, diabetes mellitus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, High-density lipoprotein; CAP, Controlled Attenuation Parameter; LSM, liver stiffness measurement; LDL, low-density lipoprotein; VLDL, Very-low-density lipoprotein